0001626199-24-000074.txt : 20240510 0001626199-24-000074.hdr.sgml : 20240510 20240510192513 ACCESSION NUMBER: 0001626199-24-000074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DURAND REMY CENTRAL INDEX KEY: 0001973027 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 24936551 MAIL ADDRESS: STREET 1: C/O ALPINE IMMUNE SCIENCES, INC. STREET 2: 185 EAST BLAINE STREET, SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98012 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4 1 wk-form4_1715383504.xml FORM 4 X0508 4 2024-05-08 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001973027 DURAND REMY C/O ALPINE IMMUNE SCIENCES, INC. 188 EAST BLAINE STREET, SUITE 200 SEATTLE WA 98102 0 1 0 0 Chief Business Officer 0 Common Stock 2024-05-08 4 M 0 9845 13.20 A 47949 D Common Stock 2024-05-08 4 M 0 25000 6.51 A 72949 D Common Stock 2024-05-08 4 M 0 12365 4.09 A 85314 D Common Stock 2024-05-08 4 M 0 38078 3.23 A 123392 D Common Stock 2024-05-08 4 M 0 10000 4.76 A 133392 D Stock Option (Right to buy) 13.20 2024-05-08 4 M 0 9845 0 D 2031-01-04 Common Stock 9845 70155 D Stock Option (Right to buy) 6.51 2024-05-08 4 M 0 25000 0 D 2029-02-05 Common Stock 25000 0 D Stock Option (Right to buy) 4.09 2024-05-08 4 M 0 12365 0 D 2029-06-12 Common Stock 12365 2635 D Stock Option (Right to buy) 3.23 2024-05-08 4 M 0 38078 0 D 2030-01-22 Common Stock 38078 26922 D Stock Option (Right to buy) 4.76 2024-05-08 4 M 0 10000 0 D 2028-11-05 Common Stock 10000 0 D Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024. The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. One-fourth (1/4) of the shares subject to the option will vest on May 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. One-fourth (1/4) of the shares subject to the option will vest on October 8, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. /s/ James Paul Rickey, attorney-in-fact 2024-05-10